<SEC-DOCUMENT>0001437749-25-000801.txt : 20250110
<SEC-HEADER>0001437749-25-000801.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110083242
ACCESSION NUMBER:		0001437749-25-000801
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NRX Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001719406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822844431
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38302
		FILM NUMBER:		25520592

	BUSINESS ADDRESS:	
		STREET 1:		1201 ORANGE STREET
		STREET 2:		SUITE 600
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801
		BUSINESS PHONE:		484-254-6134

	MAIL ADDRESS:	
		STREET 1:		1201 ORANGE STREET
		STREET 2:		SUITE 600
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Big Rock Partners Acquisition Corp.
		DATE OF NAME CHANGE:	20171012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nrxp20250109_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:nrxp="http://www.nrxp.com/20250106"><head>
	<title>nrxp20250109_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 1/9/2025 8:58:40 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-336">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-337">0001719406</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="nrxp-20250106.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-06</xbrli:startDate>
<xbrli:endDate>2025-01-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:CommonStockParValue0001PerShareCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-06</xbrli:startDate>
<xbrli:endDate>2025-01-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001719406</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:WarrantsToPurchaseOneShareOfCommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-06</xbrli:startDate>
<xbrli:endDate>2025-01-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b>&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b>&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM</b>&#160;<ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-17"><b>8-K</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b>&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO SECTION</b>&#160;<b>13 OR 15(d)</b>&#160;<b>OF THE</b>&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-30"><b>January 6, 2025</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-34"><b>NRX PHARMACEUTICALS, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-43"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:17.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-48"><b>001-38302</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-53"><b>82-2844431</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction<br/>
			of incorporation)</div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:17.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission<br/>
			File Number)</div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer<br/>
			Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-70"><b>1201 Orange Street</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine2" id="ixv-72"><b>Suite 600</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-76"><b>Wilmington</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-78"><b>Delaware</b></ix:nonNumeric></b> <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-80"><b>19801</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:2.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-90"><b>484</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-92"><b>254-6134</b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N/A</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-363">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-364">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-365">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-366">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;width:1%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;width:1%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which</b><br/>
			<b>registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare" name="dei:Security12bTitle" id="ixv-367">Common Stock, par value $0.001 per&#8239;share</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare" name="dei:TradingSymbol" id="ixv-368">NRXP</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-369">Nasdaq</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock" name="dei:Security12bTitle" id="ixv-370">Warrants to purchase one share of &#8239;Common Stock</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align:middle;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock" name="dei:TradingSymbol" id="ixv-371">NRXPW</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:1%;">&#160;</td>
			<td style="vertical-align:middle;width:16.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-372">Nasdaq</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-373">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#9744;&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 1.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Entry into a Material Definitive Agreement</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 5, 2025, NRx Pharmaceuticals, Inc. (the &#8220;<i>Company</i>&#8221;) entered into a binding term sheet defining the terms of a share purchase agreement (&#8220;<i>SPA</i>&#8221;) by and between the Company, HOPE Therapeutics, Inc., a wholly-owned subsidiary of the Company (&#8220;<i>HOPE</i>&#8221;), and JGS Holdings LLC, a Wyoming Limited Liability Company (the &#8220;<i>Investor</i>&#8221;), whereby the Investor intends to purchase: (i) $25.0 million in shares of HOPE&#8217;s Series A Preferred Stock convertible into one-third of all fully diluted outstanding equity of HOPE; and (ii) 730,000 shares of the Company&#8217;s common stock, par value $0.001 per share (&#8220;<i>Common</i> <i>Stock</i>&#8221;) at a price of $2.74 per share, for an aggregate purchase price of $2.0 million.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As consideration for the investment, the Investor shall receive (i) warrants to purchase 3.0 million shares of Common Stock, which warrants have a term of two years, are exercisable at a price of $3.00 per share, and shall become fully vested upon payment of the investment amounts above; (ii) an additional 500,000 shares of Common Stock by way of sale from a certain stockholder of the Company at a purchase price of $2.75 per share within 60 days of such shares being available; (iii) conditional participation rights in certain future equity financing transactions; (iv) certain royalty rights; (v) the right to appoint a designee to sit on the Board of Directors of Hope; and (vi) the right to appoint a designee as a member on the Board of Directors of the Company until the date of the Company&#8217;s next annual meeting of shareholders, following completion of certain disclosure requirements as prescribed by each of the Securities and Exchange Commission and the Nasdaq Capital Market. The Term Sheet also provides for registration rights of the Common Stock issued to the investor.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Availability of capital under the Term Sheet is conditioned upon the completion of due diligence and the execution of definitive agreements and is subject to terms and conditions of the SPA.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A copy of the press release announcing the entrance into the Term Sheet is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 3.02 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Unregistered Sales of Equity Securities</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The shares are being offered and sold to the Investor by the Company in a transaction that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;<i>Securities Act</i>&#8221;), in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D thereunder.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 8.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Other Events</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">See Item 1.01</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9.01. </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)&#160;Exhibits</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b><b> No.</b></div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 92%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_764005.htm" style="-sec-extract:exhibit;">Term Sheet, dated as of January 5, 2025, between the Company and JGS Holdings LLC</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1*</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_764006.htm" style="-sec-extract:exhibit;">Press Release, dated January 6, 2025</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page&#160;Interactive Data File (formatted as Inline XBRL).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">* Furnished herewith.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td colspan="2" style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NRX PHARMACEUTICALS,</b>&#160;<b>INC.</b></div>
			</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 28%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: January 10, 2025</div>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 28%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#160;Jonathan Javitt</div>
			</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</div>
			</td>
			<td style="vertical-align: top; width: 28%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan Javitt</div>
			</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:&#160;</div>
			</td>
			<td style="vertical-align: top; width: 28%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interim Chief Executive Officer</div>
			</td>
			<td style="vertical-align: top; width: 15%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_764005.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_764005.htm</title>

	<!-- Generated by ThunderDome Portal - 1/9/2025 9:13:38 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="nrx2.jpg" src="nrx2.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NRx Pharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1201 Orange Street</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Wilmington, DE 19801</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Binding Term Sheet</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Share Purchase Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">January 5, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a summary of terms and conditions to be used as a basis for definitive agreements between NRx Pharmaceuticals, Inc., HOPE Therapeutics Inc. and JGS Holdings LLC, controlled by Dallas Sauer &amp; Anita Nunes (Sauer Nunes). This term sheet contains all material terms and conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx Pharmaceuticals, Inc. (NRXP on Nasdaq)/HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">One or more investment funds managed by Smith &amp; Sauer, LLC,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Securities</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Common Stock of NRx, Warrants to Purchase Common Stock of NRx, Preferred Stock of HOPE Therapeutics</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Commitment Amount</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor commits $2,000,000 to purchase 730,000 shares of NRx Common Stock to be registered via a filed form S-1 with the US Securities and Exchange Commission, no later than February 15, 2025. Settlement in cash shall occur no later than Friday, January 10, 2025 via wire transfer.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor commits $25,000,000 to purchase Preferred Series A shares convertible to 1/3 of all fully diluted outstanding equity of HOPE Therapeutics. The shares shall provide a current preferred dividend of 15% per annum, paid quarterly and shall be non-callable for two years from date of issue. Settlement shall occur in four tranches to be delivered via cash settlement. Final Tranche dates to be agreed upon and finalized with Hope Leadership to align with acquisitions and strategy post closing.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As consideration for the above investment, the Investor shall receive warrants to purchase 3 million shares of common stock of NRx, Inc. at a strike price of $3.00 per share with a term of 24 months from date of this agreement. Warrants shall become fully vested upon payment of the investment amounts above.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor will also receive 500k shares of founder&#8217;s stock by way of sale from Dan Javitt to be purchased at $2.75 within 60 days of it being available.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For so long as investor holds more than 50% of the preferred share position in HOPE Therapeutics or for 24 months, from closing of this transactions whichever comes sooner, The Investor shall have the right to participate in future sales of equity in NRXP and/or HOPE as follows:</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For retail, non-underwritten offerings, Investor shall have a 50% participation right.</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 54pt; text-indent: -36pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For institutional offerings to fundamental investors and or underwritten offerings, Investor shall have a 25% participation right.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor shall be entitled to receive royalties on net revenue from NRx Drug Sales up to a Cumulative Return of 250M. Cumulative return shall be defined as the sum of preferred dividends, capital appreciation and return of capital, and royalties on drug sales, based as follows:</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Initial Royalty Rate</b>: 10% of net revenue until the Investor has received cumulative returns totaling $125 million.</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Subsequent Royalty Rate</b>: 5% of net revenue until the Investor has received cumulative returns totaling $250 million.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As a consequence of the above transactions, Investor shall be considered an affiliate of the Company and shall file and maintain Schedule 13G and other relevant forms with the SEC.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Board Representation</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor shall be elected to the Board of HOPE Therapeutics. The Investor&#8217;s board representative shall retain <b>Affirmative Consent Rights</b>&nbsp;over the key decisions until a full C suite and Board is onboarded.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to completion of SEC and Nasdaq disclosure forms The Investor shall be appointed to the Board of NRx Pharmaceuticals for a term that ends contemporaneously with the next annual meeting of shareholders and shall be nominated by the nominating committee of NRx Pharmaceuticals for election by the shareholders to a three year term.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock Sales Agreement</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Investor shall be subject to the Company&#8217;s Stock Purchase and Sales Agreement and shall report all further purchases and sales of the Company&#8217;s Securities as required by law.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Registration</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All of the Common Stock in NRx Pharmaceuticals (Nasdaq:NRXP) to be issued to the Investor under this agreement shall be subject to registration rights pursuant to which the Company shall file an initial registration statement to register the resale of the shares by the Investor no later than February 15, 2025 and shall use its best efforts to have such registration statement declared effective within 60 days of the initial closing. The Company shall pay all expenses in connection with the registration, issuance, and listing of the Underlying Shares.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Conditions to Closing</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Investor will obtain all relevant approvals, including the Investors&#8217;s board of directors and consents from any controlling shareholders.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will obtain all relevant approvals, including the Company&#8217;s board of directors</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fees and Expenses</b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Company and the Investor shall be responsible for all its own fees and expenses incurred in connection with the documentation and closing of this transaction.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:59.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:41.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Confidentiality </b></p>
			</td>
			<td style="vertical-align:top;width:59.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Term Sheet and the terms contained herein shall not be disclosed by the Company to any person or entity, except (i) to the Company&#8217;s employees and legal and financial advisers for the purposes of this proposed transaction who have a need to know the information and who are made aware of and agree to be bound by this confidentiality obligation, and (ii) as may be required by law, which includes disclosure of this term sheets as a material event</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>This term sheet will expire end of business on January 5, 2025. </i></b>The above summary of indicative terms and conditions are binding and constitute an agreement, between the Company and the Investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the terms and conditions contained herein are satisfactory, please sign as indicated below. We appreciate this opportunity to work with you. We look forward to an expeditious and successful closing of this transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:50.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>AGREED TO AND ACCEPTED:</b></p>
			</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>JGS HOLDINGS LLC, a Wyoming Limited Liability Company </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On behalf of the Investor.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name: Anita Nunes</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: CEO</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name: Dallas Sauer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: President</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NRX PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u><u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>
			</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jonathan C. Javitt, MD, MPH</u></p>
			</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chairman</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:top;width:50.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:49.9%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_764006.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_764006.htm</title>

	<!-- Generated by ThunderDome Portal - 1/9/2025 9:08:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 65%;">
			<div><img alt="nrx.jpg" src="nrx.jpg"></div>
			</td>
			<td style="width: 35%;">
			<div><img alt="hope.jpg" src="hope.jpg"></div>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>HOPE Therapeutics</b>&#8482;<b>, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for </b> <b>HOPE Clinic Acquisitions and Pharmaceutical Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Anticipated capital from funds managed by Smith &amp; Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations.</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Purchase $2 million in NRx equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRx shares from existing shareholders for $2.75 per share</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRx common stock at $3.00 per share with a 24-month term.</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Smith &amp; Sauer will also be entitled to receive royalties on net revenues from NRx product sales to a defined rate of return</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Investment in HOPE Therapeutics is expected to enhance NRXP's balance sheet value, strengthening its financial position.</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Smith &amp; Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals</i>&#8217;<i>&nbsp;Boards of Directors</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">MIAMI, FL, January 6, 2025 &#8211; HOPE Therapeutics&#8482;, Inc., (&#8220;HOPE&#8221;), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (&#8220;NRx&#8221;, and collectively with HOPE, the &#8220;Company&#8221;) (Nasdaq:NRXP), today announced signing of a Binding Term Sheet with Smith &amp; Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025, as recently forecast by independent securities analysts. An additional $2 million equity investment in NRx Pharmaceuticals will be used to advance the Company&#8217;s new drug applications for NRX-100 and NRX-101.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;We are honored to partner with NRx and HOPE to tackle the pressing mental health challenges facing our nation, particularly within the military and veteran communities,&#8221; said Dallas Sauer, Co-Founder of Smith &amp; Sauer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;This partnership underscores the critical importance of addressing mental health with innovative and accessible solutions," said Anita Nunes, Co-Founder of Smith &amp; Sauer. "We are proud to support HOPE and NRx in their mission to bring transformative care to underserved communities, including our veterans and military families."</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 65%;">
			<div><img alt="nrx.jpg" src="nrx.jpg"></div>
			</td>
			<td style="width: 35%;">
			<div><img alt="hope.jpg" src="hope.jpg"></div>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;We wholeheartedly welcome Smith &amp; Sauer and its founders, Mr. Dallas Sauer &amp; Ms. Anita Nunes, to the NRx and HOPE family. Smith &amp; Sauer&#8217;s long term strategic vision is well aligned with ours and we look forward to a productive relationship for years to come,&#8221; said Jonathan Javitt, MD MPH Chairman of NRx Pharmaceuticals. &#8220;In addition to Smith &amp; Sauer&#8217;s investment and business acumen, their organization has decades of experience in design and implementation of health information technology systems that will be key to the integration of HOPE&#8217;s global network of clinics.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The binding Term Sheet, to be disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission, provides $25 Million in Series A Preferred Stock convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend and product royalties up to a total of $250 million in cumulative returns to the investor. Smith &amp; Sauer will also purchase $2 million in NRx common stock at $2.75 per share. In consideration for the combined investment, Smith &amp; Sauer shall receive warrants to purchase 3 million shares of currently unregistered shares of NRx common stock at $3.00 per share with a 24 month term. Additionally, Smith &amp; Sauer will have the right to designate a director to join the HOPE Therapeutics and NRx Pharmaceuticals&#8217; Boards of Directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transactions contemplated by the Term Sheet are subject to execution of definitive agreements and the satisfaction of standard closing conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Smith &amp; Sauer</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Founded by Dallas Sauer and Anita Nunes, Smith &amp; Sauer, LLC is a private investment firm specializing in strategic partnerships and capital investments across healthcare, technology, and emerging industries. With decades of experience in operational leadership, financial structuring, and technological innovation, Smith &amp; Sauer is committed to fostering growth in mission-driven organizations. The firm&#8217;s investment philosophy centers on long-term value creation, aligning financial performance with societal impact. By leveraging its expertise in health information technology and clinic integration, Smith &amp; Sauer plays a pivotal role in advancing cutting-edge solutions to address critical healthcare challenges.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About HOPE Therapeutics, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HOPE Therapeutics, Inc. (<u>www.hopetherapeutics.com</u>) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 65%;">
			<div><img alt="nrx.jpg" src="nrx.jpg"></div>
			</td>
			<td style="width: 35%;">
			<div><img alt="hope.jpg" src="hope.jpg"></div>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About NRx Pharmaceuticals, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Notice Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company&#8217;s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company&#8217;s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company&#8217;s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company&#8217;s current views with respect to future events and is subject to these and other risks, including the risk that the transactions contemplated by the LOI are not consummated, uncertainties and assumptions relating to the Company&#8217;s operations, results of operations, growth strategy, liquidity, HOPE Therapeutic&#8217;s ability to consummate the acquisitions of providers for its national network, the Company&#8217;s ability to raise adequate capital to fund such acquisitions, and the Company&#8217;s ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company&#8217;s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC&#8217;s website at&nbsp;<u>http://www.sec.gov</u>. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;"><b>For further information: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;">Matthew Duffy</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;">Chief Business Officer, NRx Pharmaceuticals</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;">Co-Chief Executive Officer, HOPE Therapeutics, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;"><u>mduffy@nrxpharma.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nrxp-20250106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/9/2025 9:00:10 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:nrxp="http://www.nrxp.com/20250106" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nrxp.com/20250106">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20250106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20250106_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrxp-20250106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.nrxp.com/20250106/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="nrxp_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="nrxp_CommonStockParValue0001PerShareCustomMember" name="CommonStockParValue0001PerShareCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" name="WarrantsToPurchaseOneShareOfCommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nrxp-20250106_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/9/2025 9:00:11 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.nrxp.com/20250106/role/statement-document-and-entity-information" xlink:href="nrxp-20250106.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.nrxp.com/20250106/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
<link:loc xlink:href="nrxp-20250106.xsd#nrxp_CommonStockParValue0001PerShareCustomMember" xlink:label="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:type="locator"/>
<link:loc xlink:href="nrxp-20250106.xsd#nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:label="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nrxp-20250106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/9/2025 9:00:10 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>

<link:loc xlink:href="nrxp-20250106.xsd#nrxp_CommonStockParValue0001PerShareCustomMember" xlink:label="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:type="locator"/>
<link:label xlink:label="nrxp_CommonStockParValue0001PerShareCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStockParValue0001PerShare Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:to="nrxp_CommonStockParValue0001PerShareCustomMember-label" xlink:type="arc"/>

<link:loc xlink:href="nrxp-20250106.xsd#nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:label="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WarrantsToPurchaseOneShareOfCommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:to="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember-label" xlink:type="arc"/>


</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nrxp-20250106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/9/2025 9:00:11 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.nrxp.com/20250106/role/statement-document-and-entity-information" xlink:href="nrxp-20250106.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.nrxp.com/20250106/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="nrxp-20250106.xsd#nrxp_CommonStockParValue0001PerShareCustomMember" xlink:label="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:type="locator"/>
<link:loc xlink:href="nrxp-20250106.xsd#nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:label="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_CommonStockParValue0001PerShareCustomMember" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>hope.jpg
<TEXT>
begin 644 hope.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M:9/;3:9?3'$22L'C<^@<8Y]B!7C_ ("\=Z1X2T>:"[\(QZO<S2EFNI'7(7
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M9/#<&HVOAJP@UNZCO+Z.(+-<1,2LI'1LD#.1CGUHG#E"$^8U****S- HHHH
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)NV%%%%9FA__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>nrx2.jpg
<TEXT>
begin 644 nrx2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MKJ?A\V?$Y_ZX/_,5,\/&,6[FU#-*E6K&#BM3U$44@I:XSW0HHHH ^?OVA?\
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-N2T445H2%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nrx.jpg
<TEXT>
begin 644 nrx.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M@.73E%A]K^VB3^/;MV;?_BOTKDX_CTSC/]B#_O\ ?_6JK^T3_P ?'AWZ7/\
M[2KR6W/RBNZE1A*";1YN(KU(3:BSVQ/C@[_\P<#_ +:__6J9?C0Q_P"82/\
MO[_]:O'X>U7$K7V%/L<$L977VCU=?C(S'_D$C_O[_P#6JPGQ;9_^88!_VTKR
M:/AJOPFCZO3[&,L=B/YOP1ZDGQ19_P#F' ?]M*L)\2&?_F'C_ONO-86J]$W
MH]A3[&,LPQ*^U^"/0T\?LW_+B/\ ONNCT35#J]A]H,?E_.5VYSTKR6.3%>D>
M!VW>'R?^FS?TK&M2A&%TCLR_&5ZU?EF[JQTE%%%<1]">'_M%G$WAWZ7/_M*N
M&O/ ?B+2-+%_>6#"VVARZG. <<G\Z[C]HS_6^'?I<_\ M*O8;**.;0[:.9%=
M'MT5E89!!45V*HZ=.+.&=%5:DDSY5@;I6YH>C7NO7C6NF1>;*J&0KG'R@@?U
M%:OQ"\%OX5UHS643G3+@[HVQD1L>J'^E:WP:.?&4_P#UXO\ ^AI73*I^[YXG
ME>P?ME3D9">#]:_MLZ5]E_TP1><4W?PYQFM>/X>^(UZV0_[[%=Y'_P EJE_[
M!0_]#%4_B%XMU3PYJMI!ILD:I+"7;>F[G.*Q]K-M*/4VEA:$8RG.]D[:')S>
M#M=L83+-8N449.PYQ6<CE3@Y!'4&NV\$^/-1UK74T[4Q$XF5BC(NW! S_(&F
M>.M/TZP\26%S<(4M[P,)A&<8*D?-^3?I5QJ24N6:.2KA*<J?M:3TO;4Y,2UZ
MA\/VW>&L_P#39OZ5SVO>";:WT/[?HCR3; '*D[MZ>H_G6AX-U6VTKP-)>7D@
M2-)WQGJ3@<#WJ*LE4I^[W-<'0EAL1^\[,[G-**\\\/>+M>\0ZVL%O%%':ALR
MOLSL7TSZ]J]"7IS7'.#@[,]VC6C6CS1V/#_VC/\ 6^'?I<_^TJ]&\33RVWPN
MO9X':.6+3=Z.IP5(0$&O.?VC/];X=^ES_P"TJ]!\7_\ )(]2_P"P6?\ T"MO
ML0(^W/Y%#PGXBT_XE^"YK/4%7[4(_*NH^X;'#K_/V-8'P^\-WOA?XFW=C>KE
M?L,C12CI(F],$5XYX7\1WGAK68=0L)"LD9^9"?ED7NI]C7U/H&KZ9XFL+?5]
M/9)"4*Y_BCS@LA].@_*JJ1=*Z6S,:?+6:;^)&#&?^+VRC_J%?^SBIO&7@J+Q
M1J%O/+?_ &4PQ[ NT'.3G-5HC_Q?*4?]0G_V<5S?QANY[;7M.$$TD8-N3\C$
M?Q5,4W**3MH14<8TIN:NKG3Z#X*T[P7-)JUY?&3RT(#R *L8/4_7M7"^._%,
M/B'6D^Q$FUME*1L?XR3R?Y?E78>!_$MOXPT.?2-="37*)AE;_EJGK]1_A7G7
MC#PW-X9UQX,,;60EK>0_Q+Z?4=*UI?Q'S[G+B;?5U[)6@]SK_AUXM\JY31;]
MRT4QQ;L>=K?W?H:N>.?"]\]U:1Z0FZTN)C^Y7@)(PY;Z8'X<TSX<>$?L4/\
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G_P!F:?--+!YK2[IV!;)QZ #M6-:K&<;(WP]"5.?,S=HHHKC.\__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46708786239008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">NRX PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jan.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">82-2844431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1201 Orange Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">19801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">254-6134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001719406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_CommonStockParValue0001PerShareCustomMember', window );">CommonStockParValue0001PerShare Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per&#8239;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember', window );">WarrantsToPurchaseOneShareOfCommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase one share of &#8239;Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXPW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_CommonStockParValue0001PerShareCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_CommonStockParValue0001PerShareCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[
M](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :
M;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#
MV#<YD 27Y*IU5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @
M%$0J6B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ %$0J6@=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  41"I:N/'R
M4>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  41"I:F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !1$*EJV^; E(P4  #D6
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  41"I:GZ ;\+$"  #B#   #0              @ %F#0
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !1$*EJ7BKL<P    !,"   +
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4!08     "0 ) #X"  #'%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nrxp20250109_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nrxp.com/20250106/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nrxp-20250106.xsd</File>
    <File>nrxp-20250106_def.xml</File>
    <File>nrxp-20250106_lab.xml</File>
    <File>nrxp-20250106_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="nrxp20250109_8k.htm">nrxp20250109_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nrxp20250109_8k.htm": {
   "nsprefix": "nrxp",
   "nsuri": "http://www.nrxp.com/20250106",
   "dts": {
    "schema": {
     "local": [
      "nrxp-20250106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "nrxp-20250106_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nrxp-20250106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrxp-20250106_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nrxp20250109_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 31,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.nrxp.com/20250106/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20250109_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrxp20250109_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_CommonStockParValue0001PerShareCustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxp.com/20250106",
     "localname": "CommonStockParValue0001PerShareCustomMember",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockParValue0001PerShare Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nrxp_WarrantsToPurchaseOneShareOfCommonStockCustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nrxp.com/20250106",
     "localname": "WarrantsToPurchaseOneShareOfCommonStockCustomMember",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsToPurchaseOneShareOfCommonStock Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.nrxp.com/20250106/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001437749-25-000801-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-000801-xbrl.zip
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MNCP1,7O*PVB7M8 &SHX3!<QZYA[0'\\K, >0BJMB!E6(QN(2%@6C,  GX)
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M\XE33.D<,J F E.(\A9SX# 6PHG<39?<5J4H*W?5%%9PSX&R\5 "X@.91:R
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M;>U<:W<;-Y+]//X56"7CV.>0U,/Q2Y)UAI:L1+$E:RQE9O?3'K ;)!$U&QT
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M=RW.8:XF,N$[9>;BU0=G_8NC_M]WS][]]_E#T<]S4^:)$A>8%N@29BA>ZIR
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M@-X:*OL#Q/]!)(%FLQFHK?=PAM0BD0C)X@?(2&!.??U,PM\0UQMO,6*#A*O
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MMH(S H.%D-<;BQ!TJ0]L#DR-+P,N^.O @G*V[L#8S$2NK4HADIK9%3%'1;Q
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M7]X>YJE+7MCT6F%C+6+W(!QG%-_CF:,^O]T/GLV8\O6R$;$DUST(@_>^0OG
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M+^W^2L(_$%</L6+"1AD')R+P,,7Y9,/9$9LJXJ\81K> XPQ?CT<.XW R==W
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MEHOW;%$7C*<#*S 5^B#J$>N:G,%FJGA5!5,L+GJ-T63SP'*\ +$K$+U"F;P
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M#.P6PCSX(R(G_BIX_7]02P$"% ,4    "  41"I:+^4V4WT/   W90  #0
M            @ $     97A?-S8T,# U+FAT;5!+ 0(4 Q0    ( !1$*EK;
M S6]XQ(  '=2   -              "  :@/  !E>%\W-C0P,#8N:'1M4$L!
M A0#%     @ %$0J6IL(<XNW P  90\  !$              ( !MB(  &YR
M>' M,C R-3 Q,#8N>'-D4$L! A0#%     @ %$0J6LH#K76<!0  <#8  !4
M             ( !G"8  &YR>' M,C R-3 Q,#9?9&5F+GAM;%!+ 0(4 Q0
M   ( !1$*EIBZ\0+Y@8  .]'   5              "  6LL  !N<GAP+3(P
M,C4P,3 V7VQA8BYX;6Q02P$"% ,4    "  41"I:YR\Y&2P%  "&-@  %0
M            @ &$,P  ;G)X<"TR,#(U,#$P-E]P<F4N>&UL4$L! A0#%
M  @ %$0J6K_4T5XE%   T((  !,              ( !XS@  &YR>' R,#(U
A,#$P.5\X:RYH=&U02P4&      < !P"_ 0  .4T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>nrxp20250109_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nrxp="http://www.nrxp.com/20250106"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nrxp-20250106.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:CommonStockParValue0001PerShareCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrxp:WarrantsToPurchaseOneShareOfCommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-336">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-337">0001719406</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-30">2025-01-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-34">NRX PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-43">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-48">001-38302</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-53">82-2844431</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-70">1201 Orange Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20258K" id="ixv-72">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-76">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-78">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-80">19801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-90">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-92">254-6134</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-363">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-364">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-365">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-366">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare"
      id="ixv-367">Common Stock, par value $0.001 per&#x202f;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare"
      id="ixv-368">NRXP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d20258K_StatementClassOfStockAxis_CommonStockParValue0001PerShare"
      id="ixv-369">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock"
      id="ixv-370">Warrants to purchase one share of &#x202f;Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock"
      id="ixv-371">NRXPW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d20258K_StatementClassOfStockAxis_WarrantsToPurchaseOneShareOfCommonStock"
      id="ixv-372">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-373">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
